1 suppository VIFERON® 1000000 ME contains the active substance: interferon alpha-2b human recombinant 1000000 ME, excipients: alpha-tocopherol acetate 0.055 g, ascorbic acid 0.0081 g, sodium ascorbate 0.0162 g, disodium edetate dihydrate 0.0001 g , polysorbate-80 0.0001 g, base cocoa butter and confectionery fat up to 1 g.

Interferon alpha-2b human recombinant has antiviral, immunomodulating, antiproliferative properties, inhibits the replication of RNA and DNA viruses. The immunomodulating properties of interferon alpha-2b, such as increased macrophage phagocytic activity, increased specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity. In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which improves the efficiency of the body's own immune response to pathogenic microorganisms. When using the drug, the level of secretory immunoglobulins of class A increases, the level of immunoglobulin E is normalized, and the functioning of the endogenous system of interferon alpha-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and also regenerating properties. It has been established that with the use of VIFERON8, there are no side effects that occur with the parenteral administration of interferon alpha-2b preparations, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b. The use of VIFERON® as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy. Cocoa butter contains phospholipids, which allow synthetic toxic emulsifiers not to be used in production, and the presence of polyunsaturated fatty acids facilitates the administration and dissolution of the drug.

acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy; infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy; chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of pronounced activity, complicated by cirrhosis of the liver; infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis).

Viferon 3 № 10 1000000ME